S&P 500 7559.45 +0.21%
NASDAQ 26226.06 +0.07%
TASI 10808.43 -0.42%
Oil (WTI) 71.59 -0.68%
Oil (Brent) 76.06 -0.31%
VIX 15.59 -1.58%
Gold 4112.90 -0.67%
USD/SAR 3.75 +0.01%

Pfizer Inc.

PFE · Healthcare · · USD
24.39 USD
+0.00 (0.58%)
● Updated 2026-07-10 17:07 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score SELL Short-term (Swing)

49
/ 100
Technical 50
Trend & RS 41
Momentum 41
Fundamental (0%) 61
Macro 71
Liquidity 41
ComponentScoreWeight
Technical 50.0 40%
Trend & RS 40.8 20%
Momentum 40.6 20%
Fundamental 60.7 0%
Macro 71.2 15%
Liquidity 41.4 5%

Trade Setup

Entry 24.34
Stop Loss 23.27 (4.4%)
Target 1 (1:1) 25.43 (+4.4%)
Target 2 (2:1) 26.50 (+8.9%)
ATR(14) 0.54 (2.2%)
Risk per Share 1.08
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 79.7 +1.19
Momentum 40.6 -0.38
Quality 33.9 -0.65
Composite 51.4

Quality Scores

Piotroski F-Score 6 /9 — Average
✓ ✓ ✗ ✗ ✓ ✗ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 2.74 — Grey Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio 18.6 22.0 -15% below
P/B Ratio 1.5 4.0 Below
Dividend Yield 7.1% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
18.71
vs
Market Price
24.39
Upside
-23.3%
Margin of Safety -30.3%
Stage 1 PV (5yr FCF)27,033,101,838
Terminal Value PV79,629,659,713
Total Enterprise Value106,662,761,551

Assumptions

Base FCF5,973,017,489
Growth Rate (5yr)5.4%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
31.76%
Full Kelly
15.88%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 49/100. Estimated win rate 55%, avg win 7.9%, avg loss 4.0%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary BUY

2
Bullish Signals
2
Bearish Signals
43.95
RSI(14)
-0.4345
MACD

Relative Strength (RS) WEAK RS

39
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↓ FALLING (-20.1% vs SPY 3M)
RS vs Sector UNDERPERFORMING (Healthcare)
RS New High No (61d since high)
Sector Outperformance -12.3% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
WEAK RS: Underperformer — the stock is lagging the market. Avoid until RS trend reverses upward.

Technical Indicators

IndicatorValueSignal
Rsi 43.95 NEUTRAL
Macd -0.4345 BULLISH
Ma Cross 25.38 / 25.29 GOLDEN CROSS
Trend Short BELOW SMA50
Trend Long BELOW SMA200
Bollinger MIDDLE
Volume 0.04x LOW

Key Levels

LevelPrice
52-Week High28.75
Bollinger Upper26.49
SMA(200)25.29
SMA(50)25.38
SMA(20)24.72
Current Price24.39
Bollinger Lower22.95
52-Week Low23.11
ATR(14)0.54

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

Insufficient data for Wyckoff analysis.

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-06 Normal 1.17x Normal bar — no special VSA pattern
2026-07-07 Normal 0.88x Normal bar — no special VSA pattern
2026-07-08 Normal 0.76x Normal bar — no special VSA pattern
2026-07-09 No Supply 0.58x Low volume, narrow spread, firm close — no selling pressure
2026-07-10 No Supply 0.04x Low volume, narrow spread, firm close — no selling pressure

Ichimoku Cloud BEARISH

LineValueStatus
Tenkan-sen (9) 24.09 Below Kijun
Kijun-sen (26) 25.05 Base line
Senkou A 24.57 Leading span A
Senkou B 25.38 Leading span B
Cloud 24.57 – 25.38 Bearish (Red)
Price vs Cloud 24.34 Below Cloud
Chikou Span 25.34 Bearish
Alignment Score 0/4 BEARISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BEARISH FADING
BB: 22.95 – 26.49  |  KC: 23.85 – 25.6

Divergences (last 60 bars)

No significant divergences detected in the last 60 bars.

Anchored VWAP

VWAP: 24.82 Anchor: 2025-08-01 (52w Low) BELOW AVWAP -1.9%

Heikin-Ashi Trend

BULLISH Full data via /api/advanced/PFE

Valuation

MetricValue
Market Cap139.01B
P/E (TTM)18.62
Forward P/EN/A
P/B1.54
EPS1.31

Financial Health

MetricValue
Revenue Growth5.4%
Profit Margin11.8%
ROE8.3%
Debt/Equity71.60
Current Ratio1.25
Dividend Yield7.1%
Payout RatioN/A
Beta0.31

Trading Data

24.39
Open
24.39
Day High
24.39
Day Low
3.47M
Volume (0.1x avg)

Recent News (8)

McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait
24/7 Wall St. · 2026-07-10
JNJ Stock Keeps Climbing. Should You Climb On?
Trefis · 2026-07-10
Jim Cramer on Pfizer: “I Can’t Come Up With Where the Growth Is”
Insider Monkey · 2026-07-10
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
StockStory · 2026-07-10
Market Chatter: Pfizer's Vaccine Disputes With Poland, Romania Continue
MT Newswires · 2026-07-10
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
Investor's Business Daily · 2026-07-09
AstraZeneca and Ionis Stocks Sink on Trial Miss—Maybe Too Much
Barrons.com · 2026-07-09
Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?
Simply Wall St. · 2026-07-09

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —